Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

ClinicalTrials.gov ID: NCT04767529

Public ClinicalTrials.gov record NCT04767529. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in non-cirrhotic subjects with biopsy-proven F2 - F3 NASH.

Study identification

NCT ID
NCT04767529
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Akero Therapeutics, Inc
Industry
Enrollment
128 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 15, 2021
Primary completion
May 1, 2024
Completion
May 1, 2024
Last update posted
Jun 17, 2025

2021 – 2024

United States locations

U.S. sites
54
U.S. states
16
U.S. cities
47
Facility City State ZIP Site status
Akero Clinical Study Site Chandler Arizona 85224
Akero Clinical Study Site Glendale Arizona 85304
Akero Clinical Study Site Tucson Arizona 85712
Akero Clinical Study Site North Little Rock Arkansas 72117
Akero Clinical Study Site Chula Vista California 91910
Akero Clinical Study Site Fresno California 93720
Akero Clinical Study Site La Jolla California 92037
Akero Clinical Study Site Los Angeles California 90036
Akero Clinical Study Site Los Angeles California 90048
Akero Clinical Study Site Los Angeles California 90057
Akero Clinical Study Site Orange California 92866
Akero Clinical Study Site Panorama City California 91402
Akero Clinical Study Site Rialto California 92866
Akero Clinical Study Site Santa Ana California 92704
Akero Clinical Study Site Fort Myers Florida 33912
Akero Clinical Study Site Inverness Florida 34452
Akero Clinical Study Site Lakewood Rch Florida 34211
Akero Clinical Study Site Miami Florida 33134
Akero Clinical Study Site Miami Florida 33147
Akero Clinical Study Site Miami Lakes Florida 33016
Akero Clinical Study Site Ocala Florida 34471
Akero Clinical Study Site Sarasota Florida 94240
Akero Clinical Study Site Marietta Georgia 30060
Akero Clinical Study Site Topeka Kansas 66606
Akero Clinical Study Site Baton Rouge Louisiana 70809
Akero Clinical Study Site Marrero Louisiana 70072
Akero Clinical Study Site Ypsilanti Michigan 48197
Akero Clinical Study Site Flowood Mississippi 39232
Akero Clinical Study Site Jackson Mississippi 39216
Akero Clinical Study Site Las Vegas Nevada 89106
Akero Clinical Study Site Charlotte North Carolina 28204
Akero Clinical Study Site Durham North Carolina 27712
Akero Clinical Study Site Morehead City North Carolina 28557
Akero Clinical Study Site Cincinnati Ohio 45219
Akero Clinical Study Site Greenville South Carolina 29605
Akero Clinical Study Site Hermitage Tennessee 37076
Akero Clinical Study Site Nashville Tennessee 37211
Akero Clinical Study Site Arlington Texas 76012
Akero Clinical Study Site Austin Texas 78757
Akero Clinical Study Site Cedar Park Texas 75246
Akero Clinical Study Site Dallas Texas 75234
Akero Clinical Study Site Dallas Texas 75246
Akero Clinical Study Site Edinburg Texas 78539
Akero Clinical Study Site Fort Worth Texas 76104
Akero Clinical Study Site Garland Texas 75044
Akero Clinical Study Site Houston Texas 77058
Akero Clinical Study Site San Antonio Texas 78209
Akero Clinical Study Site San Antonio Texas 78215
Akero Clinical Study Site San Antonio Texas 78229
Akero Clinical Study Site San Marcos Texas 78666
Akero Clinical Study Site Webster Texas 77598
Akero Clinical Study Site Charlottesville Virginia 22908
Akero Clinical Study Site Richmond Virginia 23249
Akero Clinical Study Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04767529, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2025 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04767529 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →